SLC5A1 and cystic fibrosis: Because sotagliflozin is an inhibitor of the glucose transporter SGLT1, which is expressed in the airway epithelial cells (35), one concern of using this drug for CF is that the elevated glucose level in the airway lumen may aggravate the lung infections.